异丙托溴铵联合β_(2)受体激动剂治疗慢阻肺急性加重期的临床疗效及对肺功能的影响  

Clinical Efficacy of Ipratropium Bromide Combined withβ_(2)Receptor Agonist in the Treatment of Acute Exacerbation of COPD and Its Effect on Lung Function

作　　者：马显华 MA Xianhua(Department of General Medicine,Panzhou People's Hospital,Panzhou 561600,Guizhou,China)

机构地区：[1]盘州市人民医院全科医学科,贵州盘州561600

出　　处：《系统医学》2025年第2期62-65,共4页Systems Medicine

摘　　要：目的评估在慢性阻塞性肺疾病(慢阻肺)急性发作期同步应用异丙托溴铵和β_(2)受体激动剂的临床效果以及对肺功能的改善情况。方法非随机选取盘州市人民医院2022年11月—2023年11月期间收治的61例慢阻肺急性加重患者,按治疗方法不同分为观察组(n=31)和对照组(n=30)。观察组采取异丙托溴铵联合β_(2)受体激动剂治疗,对照组采取β_(2)受体激动剂治疗,对比两组患者的治疗效果、血气指标、肺功能、不良反应发生率。结果与对照组治疗总有效率76.67%(23/30)相比较,观察组的96.77%(30/31)更高,差异有统计学意义(χ^(2)=17.554,P<0.05);治疗后,观察组血气指标、肺功能指标优于对照组,差异有统计学意义(P均<0.05);观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论对慢阻肺急性加重期患者采取异丙托溴铵联合β_(2)受体激动剂治疗,能够有效提高治疗效果,改善血气指标与肺功能,且药物不良反应少。Objective To study the clinical efficacy of ipratropium bromide combined withβ_(2)receptor agonist in the treatment of acute exacerbation of COPD and its effect on lung function.Methods From November 2022 to November 2023,a total of sixty-one patients with COPD exacerbation in Panzhou People's Hospital were non-randomly selected.They were divided into two groups according to different treatment methods.The observation group(n=31)received ipratropium bromide in combination with aβ_(2)receptor agonist,and the control group(n=30)was given only theβ_(2)receptor agonist.The treatment effect,blood gas index,lung function,and the incidence of adverse reactions were compared between the two groups.Results Compared with the total response rate of 76.67%(23/30)in the control group,the observation group of 96.77%(30/31)was better,and the difference was statistically significant(χ^(2)=17.554,P<0.05).After treatment,the blood gas index and lung function index of the observation group were better than those in the control group,and the differences were statistically significant(all P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion The paired usage of ipratropium bromide andβ_(2)agonists greatly enhances therapeutic outcomes,improving blood gas indices and lung function.This combination therapy can reduce the incidence of adverse effects.

关 键 词：慢性阻塞肺疾病急性加重期 异丙托溴铵 β_(2)受体激动剂 临床疗效 

分 类 号：R4[医药卫生—临床医学]